Agents and Actions

, Volume 15, Issue 5–6, pp 520–524 | Cite as

Cisplatinum: A review, with special reference to cellular and molecular interactions

  • Charles L. Litterst
Immunosuppression and Inflammation Editorial


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    C.L. Litterst, T.E. Gram, R.L. Dedrick, A.F. LeRoy andA.M. Guarino,Distribution and disposition of platinum following intravenous administration of cisdichlorodiammineplatinum (II) to dogs, Cancer Res.36, 2340–2344 (1976).PubMedGoogle Scholar
  2. [2]
    R.G. Pretorius, E.S. Petrilli, C. Kean, L.C. Ford, J. D. Hoeschele andK.D. Lagasse,Comparison of IV and IP routes of administration of cisplatin in dogs, Cancer Treat. Reports65, 1055–1062 (1981).Google Scholar
  3. [3]
    J.J. Gullo, C.L. Litterst, P.J. McGuire, B.I. Sikic, D.F. Hoth andP.V. Wooley,Pharmacokinetics and protein binding of cisdichlorodiammineplatinum (II) adminstered as a 1 hour or as a 20 hour infusion. Cancer Chemother. Pharmacol.5, 21–26 (1980).CrossRefPubMedGoogle Scholar
  4. [4]
    C.L. Litterst, A.F. LeRoy andA.M. Guarino,Disposition and distribution of platinum following parenteral administration of cisdichlorodiammine platinum (II) to animals, Cancer Treat. Reports63, 1485–1482 (1979).Google Scholar
  5. [5]
    F. Bertolero andC.L. Litterst,Changes in renal handling of platinum in cisplatinum-treated rats following induction of metabolic acidosis or alkalosis, Res. Comm. Chem. Path. Pharmacol.36, 273–285 (1982).Google Scholar
  6. [6]
    P.A. DeSimone, R.S. Yancey, J.J. Coupal, J.D. Butts andJ.D. Hoeschele,Effect of a forced diuresis on distribution and excretion (via urine and bile) of 195m platinum when given as 195m platinum cisdichlorodiammineplatinum (II), Cancer Treat. Reports63, 951–960 (1979).Google Scholar
  7. [7]
    R.S. Goldstein, B. Noordwier, J.T. Bond, J.B. Hook andG.H. Mayor,Cisdichlorodiammine-platinum nephrotoxicity: time course and dose response of renal funtional impairment, Toxic appl. Pharmac.60, 165–175 (1981).CrossRefGoogle Scholar
  8. [8]
    J.M. Hill, E. Loeb, A. MacLellan, R.O. Hill, A. Khan andJ. J. King,Clinical studies of platinum coordination compounds in the treatment of various malignant diseases, Cancer Chemother. Reports59, 647–659 (1975).Google Scholar
  9. [9]
    C. Litterst andV. Schweitzer,Increased tissue deposition and decreased excretion of platinum following administration of cisplatinum to cisplatinum-pretreated animals, Cancer Chemother. Pharmacol.12, 46–49 (1984).CrossRefPubMedGoogle Scholar
  10. [10]
    R.C. Manaka andW. Wolf,Distribution of cisplatin in blood, Chem. Biol. Interact.22, 353–358 (1978).CrossRefPubMedGoogle Scholar
  11. [11]
    D. Choie, A. del, Campo andA.M. Guarino,Subcellular localization of cisdichlorodiammine-platinum (II) in rat liver and kidney, Toxic appl. Pharmac.55, 245–252 (1980).CrossRefGoogle Scholar
  12. [12]
    C.L. Litterst, S. Tong, Y. Hirokata andZ.H. Siddik,Alterations in hepatic and renal levels of glutathione and activities of glutathione S-transferases from rats treated with cisdichlorodiammineplatinum-II, Cancer Chemother. Pharmacol.8, 67–71 (1982).CrossRefPubMedGoogle Scholar
  13. [13]
    P.T. Daley-Yates andD.C.H. McBrien,Cisplatin metabolites: a method for their separation and for measurement of their renal clearance in vivo, Biochem. Pharmac.32, 181–184 (1983).CrossRefGoogle Scholar
  14. [14]
    C.L. Litterst,Alterations in the toxicity of cisdichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of adminstration, Toxic appl. Pharmac.61, 99–108 (1981).CrossRefGoogle Scholar
  15. [15]
    R.G. Ozols, A.B. Deiseroth, N. Javadpour, A. Barlock, G. Messerschmidt andR.C. Young,Treatment of poor prognosis non-seminomatous testicular cancer with a ‘high dose’ platinum combination chemotherapy regimen, Cancer51, 1803–1807 (1983).PubMedGoogle Scholar
  16. [16]
    Y. Nakai, K. Konishi, K.C. Chang, K. Ohashi, N. Morisaki, Y. Minowa andA. Morimots,Ototoxicity of the anticancer drug cisplatin. An experimental study, Acta Otolaryngol.93, 227–232 (1982).PubMedGoogle Scholar
  17. [17]
    J.L. Aull, R.L. Allen, A.R. Bapat, H.H. Daron, M.E. Friedman andJ.F. Wilson.Effects of platinum complexes on seven enzymes, Biochem. biophys. Acta571, 352–358 (1979).PubMedGoogle Scholar
  18. [18]
    C.L. Litterst, S. Tong, Y. Hirokata andZ.H. Siddik,Stimulation of microsomal drug oxidation in liver and kidney of rats treated with the oncolytic agent cisdichlorodiammineplatinum (II), Pharmacology27, 46–53 (1983).PubMedGoogle Scholar
  19. [19]
    A.M. Gaurino, D.S. Miller, S.T. Arnold, J.B. Pritchard, R.D. Davis, M.A. Urbanek, T.J. Miller andC.L. Litterst,Platinate toxicity — past, present and future, Cancer Treat. Reports63, 1475–1483 (1979).Google Scholar
  20. [20]
    P.T. Daley-Yates andD.C.H. McBrien, Cisplatin (cisdichlorodiammineplatinum II) nephrotoxity. InNephrotoxicity: Assessment and Pathogenesis (EdsP.H. Bach, F.W. Bonner, J.W. Bridges andE. A. Lock). John Wiley & Sons, NY 1982.Google Scholar
  21. [21]
    S.K. Aggarwal, M.W. Whitehouse andC. Ramachandran, Ultrastructural effects of cisplatin. InCisplatin: Current Status and New Developments (EdsA.W. Prestayko, S.T. Crooke andS.K. Carter). Academic Press, NY 1980.Google Scholar

Copyright information

© Birkhäuser Verlag 1984

Authors and Affiliations

  • Charles L. Litterst
    • 1
  1. 1.Laboratory of Medicinal Chemistry and Pharmacology, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer InstituteNational Institutes of HealthBethesda

Personalised recommendations